Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Immunisation
Healthy Volunteers

Interventions

BIOLOGICAL: Quadrivalent RIV with H3 strain 1
BIOLOGICAL: Quadrivalent RIV with H3 strain 1 and adjuvant
BIOLOGICAL: Quadrivalent RIV with H3 strain 2
BIOLOGICAL: Quadrivalent RIV with H3 strain 2 and adjuvant
BIOLOGICAL: Quadrivalent RIV with 2018-2019 NH H3 strain
BIOLOGICAL: Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant

Sponsor

Sanofi Pasteur, a Sanofi Company